Literature DB >> 2578543

Interferon enhances the susceptibility of virus-infected fibroblasts to cytotoxic T cells.

J F Bukowski, R M Welsh.   

Abstract

Interferon (IFN) pretreatment of low-passage mouse embryonic fibroblasts (MEF) infected with lymphocytic choriomeningitis virus or vaccinia virus rendered these cells two to three times more susceptible to lysis by H-2 restricted, virus-specific cytotoxic T lymphocytes (CTL) than control, virus-infected MEF. The increased sensitivity to lysis correlated with increased expression of surface H-2 antigens, but not viral antigens. Continuous cell lines already highly sensitive to CTL-mediated lysis and already expressing high levels of surface H-2 antigens were unaffected by IFN pretreatment. These results suggest that IFN treatment, by increasing surface H-2 levels, may result in increased association of surface H-2 and virus antigens, leading to enhanced recognition and lysis by virus-specific CTL.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2578543      PMCID: PMC2187545          DOI: 10.1084/jem.161.1.257

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  17 in total

1.  Selective neutralization by antiinterferon globulin of macrophage activation by L-cell interferon, Brucella abortus ether extract, Salmonella typhimurium lipopolysaccharide, and polyanions.

Authors:  R M Schultz; M A Chirigos
Journal:  Cell Immunol       Date:  1979-11       Impact factor: 4.868

2.  Interferon inhibits mouse leukaemia virus release: an electron microscope study.

Authors:  E H Chang; S J Mims; T J Triche; R M Friedman
Journal:  J Gen Virol       Date:  1977-02       Impact factor: 3.891

3.  Immune interferon release when a cloned cytotoxic T-cell line meets its correct influenza-infected target cell.

Authors:  A G Morris; Y L Lin; B A Askonas
Journal:  Nature       Date:  1982-01-14       Impact factor: 49.962

4.  Regulation of the production of immune interferon and cytotoxic T lymphocytes by interleukin 2.

Authors:  W L Farrar; H M Johnson; J J Farrar
Journal:  J Immunol       Date:  1981-03       Impact factor: 5.422

5.  Increase in NK cell number and turnover rate during acute viral infection.

Authors:  C A Biron; L R Turgiss; R M Welsh
Journal:  J Immunol       Date:  1983-09       Impact factor: 5.422

6.  Interferon induction by lymphocytic choriomeningitis viruses correlates with maximum virulence.

Authors:  S Jacobson; R M Friedman; C J Pfau
Journal:  J Gen Virol       Date:  1981-12       Impact factor: 3.891

7.  Interferon treatment of mice: enhanced expression of histocompatibility antigens on lymphoid cells.

Authors:  P Lindahl; I Gresser; P Leary; M Tovey
Journal:  Proc Natl Acad Sci U S A       Date:  1976-04       Impact factor: 11.205

8.  Interferon-gamma induces enhanced expression of Ia and H-2 antigens on B lymphoid, macrophage, and myeloid cell lines.

Authors:  G H Wong; I Clark-Lewis; L McKimm-Breschkin; A W Harris; J W Schrader
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

9.  H-2 compatability requirement for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus. Different cytotoxic T-cell specificities are associated with structures coded for in H-2K or H-2D;.

Authors:  R M Zinkernagel; P C Doherty
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

10.  Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis.

Authors:  G Trinchieri; D Santoli
Journal:  J Exp Med       Date:  1978-05-01       Impact factor: 14.307

View more
  30 in total

1.  Heterogeneity of cytokine functions in HIV infection.

Authors:  S K Kundu; T C Merigan
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

Review 2.  Heterologous immunity between viruses.

Authors:  Raymond M Welsh; Jenny W Che; Michael A Brehm; Liisa K Selin
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

3.  IFN-alpha beta and self-MHC divert CD8 T cells into a distinct differentiation pathway characterized by rapid acquisition of effector functions.

Authors:  Heather D Marshall; Amanda L Prince; Leslie J Berg; Raymond M Welsh
Journal:  J Immunol       Date:  2010-06-30       Impact factor: 5.422

4.  The effect of interferon-gamma treatment of rat tumour cells on their susceptibility to natural killer cell, macrophage and cytotoxic T-cell killing.

Authors:  H Yeoman; R A Robins
Journal:  Immunology       Date:  1988-02       Impact factor: 7.397

5.  Enhanced susceptibility to cytotoxic T lymphocytes of target cells isolated from virus-infected or interferon-treated mice.

Authors:  J F Bukowski; R M Welsh
Journal:  J Virol       Date:  1986-09       Impact factor: 5.103

Review 6.  Interactions of viruses with the immune system.

Authors:  C A Mims
Journal:  Clin Exp Immunol       Date:  1986-10       Impact factor: 4.330

7.  Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen.

Authors:  L M Mylin; R H Bonneau; J D Lippolis; S S Tevethia
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes.

Authors:  J F Bukowski; I Kurane; C J Lai; M Bray; B Falgout; F A Ennis
Journal:  J Virol       Date:  1989-12       Impact factor: 5.103

9.  Relation of H-2 expression on murine RCT(+) sarcoma cells to lung colonization and sensitivity to NK cells.

Authors:  K Masuyama; H Ochiai; S Ishizawa; K Tazawa; S Niwayama; M Fujimaki
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

10.  Lipopolysaccharide augments HLA-A,B,C molecule expression but inhibits interferon-gamma-induced HLA-DR molecule expression on cultured human endothelial cells.

Authors:  A Otsuka; T Hanafusa; N Kono; S Tarui
Journal:  Immunology       Date:  1991-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.